Volume : 13, Issue : 04, April – 2026

Title:

A BEIFE REVIEW ON HERBAL ANTIPARKINSON’S DRUG

Authors :

Cheke.P.R , Chitte. M.G, Tathe.P.R

Abstract :

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra of the midbrain. loss of dopaminergic neuron in the substantia nigra pars compacta of the brain. With its incidence rising annually, the multi-mechanistic pathogenesis of PD presents new opportunities for the development of multi-target therapies. While previous studies have explored the therapeutic potential of natural products in PD, existing reviews often focus on single mechanisms or a limited number of compounds. While previous studies have explored the therapeutic potential of natural products in PD, existing reviews often focus on single mechanisms or a limited number of compounds. This article systematically evaluates preclinical studies published between 2018 and 2025, encompassing 32 bioactive components and 10 categories of traditional Chinese medicine (TCM) formulas. Herbal drug therefore are safer than other drugs, herbal medicine has it roots in ancient civilization .it include the use of medicine plant to cure disease and enhance general well -being.
Keywords: herbal medicine Parkinson’s, neurodegenerative, motor &non- motor symptoms, medicinal plant.

Cite This Article:

Please cite this article in press Chitte .M. G et al., A Beife Review On Herbal Antiparkinson’s Drug, Indo Am. J. P. Sci, 2026; 13(04).

REFERENCES:

1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817.
2. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.
3. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, and future of Parkinson’s disease. Lancet Neurol. 2017;16(6):464–478.
4 Khurana S, Gourie-Devi M. Epidemiology of Parkinson’s disease in India. Cureus. 2025.
5. Dhiman V, et al. Parkinson’s disease in India: prevalence and burden. Neurol India. 2021.
6. Global Burden of Disease Study 2021. Global, regional, and national burden of Parkinson’s disease. Lancet Neurol. 2021.
7. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
8. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease. Lancet Neurol. 2006;5(3):235–245.
9. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601.
10. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Mov Disord. 2009;24(S2):S1–S2.
11. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease. JAMA. 2014;311(16):1670–1683.
12. Stowe R, Ives N, Clarke CE, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008.
13. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct therapy in Parkinson’s disease. Lancet. 2005;365(9463):947–954.
14. Singh N, Bhalla M, de Jager P, Gilca M. An overview on Ashwagandha: a Rasayana (rejuvenator). Phytother Res. 2007;21(6):501–512.
15. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;106–107:17–32.
16. Manyam BV. Paralysis agitans and levodopa in Ayurveda: ancient Indian medical treatise. Mov Disord. 1995;10(6):713–716.
17. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson’s disease: a double-blind clinical study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672–1677.
18. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11(2):490–493
19. Srinivasan S, Rajasankar S, Anburajan M, et al. Neuroprotective effect of Withania somnifera root extract against MPTP-induced Parkinsonism in mice. Journal of Ethnopharmacology. 2007;114(2):280–284. doi:10.1016/j.jep.2007.08.013
20. Wongtrakul J, Tocharus J, Govitrapong P. Neuroprotective effects of Ashwagandha (KSM-66) against 6-OHDA-induced toxicity in SH-SY5Y cells. Biomedicine & Pharmacotherapy. 2021; 134:111206. doi: 10.1016/j.biopha.2020.111206
21. Kaur G, Bansal MP. Protective role of Withania somnifera against oxidative stress in Drosophila melanogaster model of neurodegeneration. Neurochemical Research. 2013;38(3):562–571. doi:10.1007/s11064-012-0954-2
22. Rajan KE, Preethi J, Singh HK. Bacopa monnieri improves cognitive function and modulates neurotransmitters. Evidence-Based Complementary and Alternative Medicine. 2015; 2015:1–9.
23. Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: A systematic review of randomized controlled trials. Journal of Alternative and Complementary Medicine. 2012;18(7):647–652. doi:10.1089/acm.2011.0367
24. Jeyasri R, Muthuramalingam P, Suba V, Ramesh M, Chen JT. Neuroprotective effects of Bacopa monnieri: A review. Biomolecules. 2020;10(3):411. doi:10.3390/biom10030411
25 . Khatri DK, Juvekar AR. Neuroprotective effect of curcumin in Parkinson’s disease. Neuroscience Letters. 2016;620:114–120.
26. Darbinyan V, et al. Therapeutic potential of curcumin in neurodegenerative diseases. Phytomedicine. 2010;17(9–10):641–647.
27. Liu Z, et al. Curcumin protects dopaminergic neurons from oxidative damage. Brain Research. 2013;1515:1–8.
28. Kosaraju J, Chinni S, Roy PD, Kannan E, Antony AS, Kumar MN. Neuroprotective effect of Tinospora cordifolia in Parkinson’s disease models. Neurochemical Research. 2014;39(12):2329–2338.
29. Biala H, Kruk-Slomka M. Protective effects of Tinospora cordifolia in neurodegeneration. Journal of Ethnopharmacology. 2015;169:1–10.
30. Dilnashin H, et al. Therapeutic potential of Tinospora cordifolia in neurodegenerative disorders. Biomedicine & Pharmacotherapy. 2019;109:1375–1382.
31. Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverris J, Ogren SO. EGb761 protects against oxidative stress in Parkinson’s model. Neuroscience. 2009;163(4):1231–1239.
32. Ahmad M, Saleem S, Ahmad AS, et al. Protective effects of Ginkgo biloba extract in 6-OHDA-induced Parkinsonism. Brain Research. 2005;1046(1–2):85–94.
33. Kim MS, Lee JI, Lee WY, Kim SE. Neuroprotective activity of Ginkgo biloba extract in Parkinson’s disease models. Neuroscience Letters. 2004;355(1–2):123–126.
34. Song X, Zhang W. Neuroprotective effects of ginseng in experimental models of Parkinson’s disease. Journal of Ethnopharmacology. 2010;127(2):419–425.
35. Zhou TT, Zu G, Zhang XG, Wang X, Li S, Gong X. Neuroprotective effects of ginsenoside Rg1 in Parkinson’s disease models. Neuropharmacology. 2016;109:75–82.
36. Chen WW, Chen G. Ginseng in neurodegenerative diseases: Mechanisms and therapeutic potential. Acta Pharmacologica Sinica. 2017;38(2):1
37. Kulkarni SK, Dhir A. Experimental evaluation of anti-Parkinsonian activity of plant extracts using haloperidol-induced catalepsy model. Indian Journal of Experimental Biology. 2006;44(3):234–23
38. Tripathi MM, Upadhyay S, Bhattacharya SK. Evaluation of motor coordination and CNS activity of herbal extracts in experimental models. Journal of Ethnopharmacology. 2008;118(3):456–461.
39. Mukherjee PK. Quality Control of Herbal Drugs: An Approach to Evaluation of Botanicals. 1st ed. New Delhi: Business Horizons; 2007.
40. Kulkarni SK, Verma A. Role of plant extracts in haloperidol-induced catalepsy in rats. Pharmacology Biochemistry and Behavior. 2005;81(2):386–391.
41. Dandiya NC, Kulkarni SK. Studies on reserpine-induced Parkinsonism and effect of herbal drugs. Indian Journal of Pharmacology. 1992;24(4):221–226.
42. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. Journal of the American Pharmaceutical Association. 1957;46(3):208–209.
43. Zhou TT, Wang XX, Li YJ, Fan Y. Neuroprotective effects of glycyrrhizin in MPTP-induced Parkinson’s disease model. Neuroscience Letters. 2015;597:85–90.
44. Kaur H, Prakash A, Medhi B. Drug therapy in Parkinson’s disease: neuroprotective role of herbal extracts. Brain Research. 2009;1283:42–50.
45. Kulkarni SK, Dhir A. Current investigational drugs for Parkinson’s disease. Indian Journal of Pharmacology. 2006;38(3):145–152